Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO

Glaxosmithkline Pharmaceuticals — Investor Presentation (May 2025)

12 slides from Glaxosmithkline Pharmaceuticals's investor presentation, May 13, 2025

1. Slide 1: GlaxoSmithKline Pharmaceuticals Limited

   GlaxoSmithKline Pharmaceuticals Limited 13th May, 2025 gsk.com

2. Slide 2: Committed to India in our second century of operations

   Committed to India in our second century of operations… Bringing together science, technology and talent to deliver impact #AheadTogether 2

3. Slide 3: Priority brands performance driving competitive edge in General Medicines

   Priority brands performance driving competitive edge in General Medicines Uniting science, Enhanced access Strengthening Maximize potential technology and talent and sharp focus market leadership in the SITT Market +0.5% 103 1.2x 120 1.1x 101 ~1.8x 137 Val growth Unit EI Vol growth Unit EI Vol growt

4. Slide 4: Key brands of General Medicines and Pediatric Vaccines deliver competitive external performance in Q4

   Key brands of General Medicines and Pediatric Vaccines deliver competitive external performance in Q4 General Medicines key brands deliver Improving our SoV and Elevating customer competitive performance experience through digital innovation Brand Unit EI Augmentin 103 Calpol 101 400K+ Ceftum* 120 U

5. Slide 5: GSK leading the Vaccines market with ~21.2% market share

   GSK leading the Vaccines market with ~21.2% market share Year 1 In clinic Promotion and Rank #1 /#2 HCP engagement Maintain Leadership Year 2 Expanding the market Ahead of market through HCO engagement & Patient Awareness (Collaboration with IAP to educated Pediatricians) Havrix & Varilrix EI>100 Ma

6. Slide 6: Building equity in respiratory segment by redefining goals for clinical outcomes

   Building equity in respiratory segment by redefining goals for clinical outcomes and through science-led differentiation 2250+ 5.9% EI 137 Severe asthma patients benefitted Val MS in cluttered SITT class Unit EI #1 Accelerate Initiation of Nucala #1 Differentiation vs other SITTs • Accelerate initia

7. Slide 7: Shingrix update across 'must wins'

   Shingrix update across ‘must wins’ Improve risk & severity perception Improve strength of HCP Improve ease of inoculation for for Shingles recommendation patients Digital screens pilot in 10 clinics – scale up plan for 300 by July’ 2025 Vaccination card roll Indian consensus out to all clinics & gui

8. Slide 8: Accolades & recognitions

   Accolades & recognitions Great Place to work - Certification Annual OPPI Awards 2024-25 EHS excellence Award 2024-25 received by Nashik manufacturing unit Winner – Sales Force Excellence Award  GSK Worli received, Adult immunization clinic set up at Fortis Leesman+ Escorts, Heart institute, Delhi –

9. Slide 9: Financial Highlights: FY Apr'24-Mar'25 (Standalone)

   Financial Highlights : FY Apr’24-Mar’25 (Standalone) Revenue EBITDA PAT (before exceptional) ₹3723cr ₹1169cr ₹915cr Growth +9% Growth +30% Growth+32% Margin: 31% Margin: 25% Revenue growth +9% EBITDA margin +500 bps (YoY) PAT +440 bps (YoY)  General Medicine key Pharma brands volume  PAT stepped u

10. Slide 10: Consistent improved Profitability and Return Ratios (Standalone)

    Consistent improved Profitability and Return Ratios (Standalone) Gross Margin EBITDA Employee Cost to Sales 31.4% 62.9% 26.4% 19.1% 18.7% 18.4% 61.9% 24.8% 23.6% 15.7% 60.7% 59.4% FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 ROCE Return on Net Worth Market Cap (Rs. Cr) 63.8% 46.9% 48,

11. Slide 11: Financial Highlights: Q4 FY25 (Standalone)

    Financial Highlights : Q4 FY25 (Standalone) Revenue EBITDA PAT (before exceptional) ₹966cr ₹331cr Growth +30% ₹260cr Growth +6% Margin: 34% Growth+36% Margin: 27% Revenue growth +6% EBITDA margin +620 bps (YoY) PAT +590 bps (YoY)  General Medicine key Pharma brands volume growth +5%; lower than exp

12. Slide 12: Thank you!

    gsk.com Thank you!

GlaxoSmithKline Pharmaceuticals — Investor Presentation (May 2025) on 6ix